Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on August 1, 2006

Published online before print May 30, 2006
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0106047v1
80/2/298    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kronenberger, B.
Right arrow Articles by Sarrazin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kronenberger, B.
Right arrow Articles by Sarrazin, C.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0106047

Received for publication January 23, 2006.
Revised March 14, 2006.
Accepted for publication April 3, 2006.

Article

Dynamics of CD81 expression on lymphocyte subsets during interferon-{alpha}-based antiviral treatment of patients with chronic hepatitis C

Bernd Kronenberger *@, Eva Herrmann *, W. Peter Hofmann *, Heiner Wedemeyer {dagger}, Martina Sester {ddagger}, Ulrike Mihm *, Temam Ghaliai *, Stefan Zeuzem *, and Christoph Sarrazin *@

Klinik für Innere Medizin *II and {ddagger}IV, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; and {dagger}Medizinische Hochschule Hannover, Germany

@ To whom correspondence should be addressed. E-mail: bernd.kronenberger{at}email.de.


  Abstract

CD81 is a hepatitis C virus (HCV) coreceptor with important functions in lymphocytes. During treatment, CD81 expression may be changed directly by the antiviral therapy or indirectly by reduction of the HCV serum level. The regulation of CD81 on lymphocyte subtypes has not been investigated so far and may be relevant for the control of viral infection and treatment response. CD81 was analyzed by flow cytometry in CD8(+), CD4(+), CD19(+), and CD56(+) lymphocyte subtypes from 20 patients with chronic hepatitis C before, during, and after antiviral treatment with pegylated interferon-{alpha} (IFN-{alpha}) and ribavirin. A sustained virologic response (SVR) was achieved in 11 patients. Dynamics of CD81 were investigated in correlation with HCV-RNA dynamics and the outcome of therapy. During treatment, the following typical patterns of CD81 regulation were observed: down-regulation on CD8(+) T cells (P=0.022) and most significantly, on CD56(+) natural killer cells (P<0.001), transient up-regulation on CD19(+) B cells (P=0.006), and weak and late down-regulation on CD4(+) T cells (P=0.028). During treatment, CD81 expression was not associated with the HCV-RNA serum level on all lymphocyte subtypes. After end of treatment, CD81 increased again in CD8(+) and CD56(+) cells (P=0.001, P=0.002). On CD8(+) T cells post-treatment, CD81 remained lower in patients who achieved a SVR compared with patients who failed to eliminate HCV after treatment (P=0.033). Lymphocyte subsets show different patterns of CD81 response before and during antiviral treatment, which are associated with administration of IFN-{alpha} and antiviral response.

Key Words: host-cell interaction • antiviral immune response






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the Society for Leukocyte Biology.